Moderna prepares to sell COVID-19 vaccine privately as US delays booster call (US.MRNA) - 05 mai 2022
Moderna is adjusting to the new pace of demand for COVID-19 vaccines in 2022, with a strong outlook on sales globally, though it still faces some hurdles in the U.S. market. That's according to CEO Stéphane Bancel, who said the company has already deals for $21 billion worth of doses for the year — mostly from global buyers.
"This might actually provide some upside not only on sales, because there's zero sales assumed in the $21 billion, but (also) on pricing. CMS [Centers for Medicare & Medicaid Services] has basically come up saying for fiscal year 2023, which starts in October, the price for COVID-19 vaccines should be around $60," Bancel said. By comparison, the U.S. government previously purchased the doses for $16.50 in the past two years, he added.